Machine learning approaches for the identification of real-world predictors of mepolizumab response
Open Access
- 13 November 2026
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (11) , e0362402
Abstract
Background: Mepolizumab improves control and reduces clinically significant exacerbations in severe asthma patients. Further research is needed to understand factors influencing patient response. Objective: Identify predictors of response to mepolizumab using machine learning techniques. Methods: Thirty clinically relevant features from the REALITI-A dataset were analyzed. Response to mepolizumab was defined as change in clinically significant exacerbations at Year 1 post-exposure, being free from clinically significant exacerbations at Year 1, and being free from clinically significant exacerbations at both Year 1 and Year 2 post-exposure for primary, secondary, and exploratory analyses, respectively. Linear/logistic regression, random forest, and XGBoost models were tested. The best-performing model based on R 2 or classification accuracy was used for feature selection. A SHapley Additive exPlanations post-hoc analysis was conducted. Results: The primary and secondary analyses included 685 patients; the exploratory analysis included 529 patients. Using XGBoost for the primary analysis, higher pre-exposure clinically significant exacerbations rate, lower body mass index, total immunoglobulin E, lower baseline activity impairment, and lower baseline Asthma Control Questionnaire-5 score were top predictors. For the secondary analysis, the random forest model identified lower pre-exposure clinically significant exacerbations rate, residency outside the United Kingdom, and lower baseline Asthma Control Questionnaire-5 score, body mass index, and baseline activity impairment as top predictors. For the exploratory analysis, XGBoost identified residency outside the United Kingdom, and lower pre-exposure clinically significant exacerbations rate, baseline Asthma Control Questionnaire-5 score, eosinophil levels, and body mass index as top predictors. Conclusion: Machine learning models identified key predictors of response to mepolizumab, which could guide clinical decision-making and improve patient outcomes in severe asthma patients.Keywords
Funding Information
- GSK (215038)
This publication has 30 references indexed in Scilit:
- A Simulation Study of the Effect of Clinical Characteristics and Treatment Choice on Reliever Medication Use, Symptom Control and Exacerbation Risk in Moderate–Severe AsthmaAdvances in Therapy, 2024
- Effect of Individual Patient Characteristics and Treatment Choices on Reliever Medication Use in Moderate-Severe Asthma: A Poisson Analysis of Randomised Clinical TrialsAdvances in Therapy, 2024
- Efficient prediction of early-stage diabetes using XGBoost classifier with random forest feature selection techniqueMultimedia Tools and Applications, 2023
- The Impact Of Baseline Exhaled Nitric Oxide Levels And Blood Eosinophil Count On Clinical Outcomes In REALITI-AJournal of Allergy and Clinical Immunology, 2022
- Long-Term Therapy Response to Anti–IL-5 Biologics in Severe Asthma—A Real-Life EvaluationThe Journal of Allergy and Clinical Immunology: In Practice, 2021
- The management of severe asthma in 2020Biochemical Pharmacology, 2020
- Characterization of Severe Asthma WorldwideChest, 2020
- Long-term Safety and Clinical Benefit of Mepolizumab in Patients With the Most Severe Eosinophilic Asthma: The COSMEX StudyClinical Therapeutics, 2019
- Asthma exacerbations in patients with asthma and rhinitis: Factors associated with asthma exacerbation and its effect on QOL in patients with asthma and rhinitisAllergology International, 2019
- Long-term Efficacy and Safety of Mepolizumab in Patients With Severe Eosinophilic Asthma: A Multi-center, Open-label, Phase IIIb StudyClinical Therapeutics, 2016